¹ÏÝäÞ¯°×°ëÏÄÌÀ¼Ó¼õÁªºÏ»¯Ñ§Ò©¶Ô±Èµ¥Óû¯Ñ§Ò©ÖÎÁƹÚÐIJ¡Îȶ¨ÐÍÐĽÊÍ´ÓÐЧÐÔµÄMeta·ÖÎö
Ѫ֬ˮƽ,×ÜÓÐЧÂÊ
³ÂÃúÌ© Å·Àò¾ý ¿ïÈÙÈÊ ³ÂÓ¢ÄÐ ÀîÌÎ ÀèÃÀ»¶ ÃÅÁè ÕŽ¡ ÕÅÖÒÕª Òª Ä¿µÄ£ºÏµÍ³ÆÀ¼Û¹ÏÝäÞ¯°×°ëÏÄÌÀ¼Ó¼õÁªºÏ»¯Ñ§Ò©¶Ô±Èµ¥Óû¯Ñ§Ò©ÖÎÁƹÚÐIJ¡Îȶ¨ÐÍÐĽÊÍ´µÄÓÐЧÐÔ£¬ÎªÁÙ´²ÖÎÁÆÌṩÑÖ¤²Î¿¼¡£·½·¨£º¼ÆËã»ú¼ìË÷PubMed¡¢EMBase¡¢CochraneͼÊé¹Ý¡¢ÖйúÆÚ¿¯È«ÎÄÊý¾Ý¿â¡¢ÖÐÎĿƼ¼ÆÚ¿¯Êý¾Ý¿â¡¢Íò·½Êý¾Ý£¬ÊÕ¼¯¹ÏÝäÞ¯°×°ëÏÄÌÀ¼Ó¼õÁªºÏ»¯Ñ§Ò©(ÊÔÑé×é)¶Ô±Èµ¥Óû¯Ñ§Ò©(¶ÔÕÕ×é)ÖÎÁƹÚÐIJ¡Îȶ¨ÐÍÐĽÊÍ´µÄËæ»ú¶ÔÕÕÊÔÑé(RCT)£¬¶Ô·ûºÏÄÉÈë±ê×¼µÄÁÙ´²Ñо¿½øÐÐ×ÊÁÏÌáÈ¡£¬²¢²ÉÓÃCochrane 5.1.0ÖÊÁ¿ÆÀ¼Û¹¤¾ß½øÐÐÖÊÁ¿ÆÀ¼Ûºó£¬²ÉÓÃRev Man 5.3ͳ¼ÆÈí¼þ½øÐÐMeta·ÖÎö(ÐĽÊÍ´ÁÆÐ§×ÜÓÐЧÂÊ¡¢Ðĵçͼ¸ÄÉÆ×ÜÓÐЧÂÊ¡¢ÑªÖ¬Ë®Æ½)¡£½á¹û£º¹²ÄÉÈë10ÏîRCT£¬ºÏ¼Æ820Àý»¼Õß¡£Meta·ÖÎö½á¹ûÏÔʾ£¬ÊÔÑé×黼ÕßÔÚÐĽÊÍ´ÁÆÐ§×ÜÓÐЧÂÊ[RR=1.25£¬95%CI(1.17£¬1.35)£¬P0.05£¬I 20.05)¡£ÄÉÈëÑо¿µÄ»ù±¾ÐÅÏ¢Ïê¼û±í1¡£
2.2 ·½·¨Ñ§ÖÊÁ¿ÆÀ¼Û½á¹û
ËùÓÐRCT¾ùδ½øÐÐÑù±¾Á¿¹ÀËã»ò²ÉÓÃÒâÏòÐÔÖÎÁÆ·ÖÎö¡£ËùÓÃRCT¾ù²ÉÓÃËæ»ú·Ö×鷽ʽ£¬ÆäÖÐÓÐ6ÏîRCT²ÉÓÃËæ»úÊý×Ö±í·¨½øÐзÖ×é·ÖÅä[6-7£¬9-10£¬14-15]£¬ÆäÓàRCTδÃ÷È·¾ßÌåËæ»ú·½·¨¡£ËùÓÐÊÔÑé¾ùδÌá¼°Ëæ»ú·ÖÅä·½°¸Òþ²Ø»òä·¨£¬µ«¾ùÖ¸³öÁË×é¼ä»ùÏ߱ȽÏÇÒ»ùÏßˮƽÏàËÆ¶ÈÁ¼ºÃ¡£4ÏîRCTÓÐÃ÷È·µÄ²¡ÀýÄÉÈë¡¢ÌÞ³ý±ê×¼[6£¬9£¬13-14]£¬ÆäÓàRCT䱨µÀ²¡ÀýÍÑÂä»òÌÞ³ý¡£²ÉÓÃRev Man 5.3Èí¼þ½øÐÐÄÉÈëÑо¿Æ«ÒзçÏÕÆÀ¹À¡£ÄÉÈëÑо¿·½·¨Ñ§ÖÊÁ¿ÆÀ¼Û½á¹û¼ûͼ1¡£
2.3 Meta·ÖÎö½á¹û
2.3.1 ÐĽÊÍ´ÁÆÐ§×ÜÓÐЧÂÊ 9ÏîÑо¿(760Àý»¼Õß)±¨µÀÁËÐĽÊÍ´ÁÆÐ§×ÜÓÐЧÂÊ[6-11£¬13-15]£¬¸÷Ñо¿¼äÎÞͳ¼ÆÑ§ÒìÖÊÐÔ(P=0.31£¬I 2=15%)£¬²ÉÓù̶¨Ð§Ó¦Ä£Ðͺϲ¢Ð§Ó¦Á¿½øÐзÖÎö¡£Meta·ÖÎö½á¹ûÏÔʾ£¬ÊÔÑé×é(Experimental)»¼ÕßÐĽÊÍ´ÁÆÐ§×ÜÓÐЧÂÊÏÔÖø¸ßÓÚ¶ÔÕÕ×é(Control)£¬²îÒìÓÐͳ¼ÆÑ§ÒâÒå[RR=1.25£¬95%CI(1.17£¬1.35)£¬P<0.001]¡£ÐĽÊÍ´ÁÆÐ§×ÜÓÐЧÂʵÄMeta·ÖÎöÉÁÖͼ¼ûͼ2¡£
2.3.2 Ðĵçͼ¸ÄÉÆ×ÜÓÐЧÂÊ 7ÏîÑо¿(576Àý»¼Õß)±¨µÀÁËÐĵçͼ¸ÄÉÆ×ÜÓÐЧÂÊ[6-7£¬9-11£¬13-14] ......
ÄúÏÖÔڲ鿴ÊÇÕªÒªÒ³£¬È«Îij¤ 8911 ×Ö·û¡£